-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO ZAI LAB’S DLL3-TARGETING ADC ZOCILURTATUG PELITECAN (ZOCI) FOR THE TREATMENT OF NEUROENDOCRINE CARCINOMAS (NECS)

Reuters·08/03/2026 11:00:01

Please log in to view news